Abstract
Colistin is used as a last-line antibiotic for the treatment of Gram-negative multiresistant bacteria. Due to its high nephrotoxicity, Therapeutic Drug Monitoring (TDM) is recommended for dose adjustment. We aimed to evaluate the available evidence of TDM in patients given colistin to treat Gram-negative infections. In this paper, we offer an overview, using an electronic search of the literature (published up to June 2019, without language restrictions) that compares the clinical outcomes and measurements of colistin TDM. Ultimately, the Therapeutic Drug Monitoring (TDM) of colistin in Plasma could prevent nephrotoxicity risk.
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference43 articles.
1. Multidrug-Resistant Gram-Negative Infections
2. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa
3. Curso Online Interpretación del Antibiograma en la Práctica Clínicahttps://cdn1.redemc.net/campus/wp-content/uploads/2018/03/ATB-01-VignoliGales-Manual-Resistencia-ES-PUB.pdf
4. Creative Commons Attribution 3.0 Unported License,2019
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献